Novo Nordisk A/S plans to launch its new obesity pill on telehealth sites like Ro and WeightWatchers as soon as it’s approved. The move is an attempt to win back market share from rival Eli Lilly and Co., which has pulled ahead in the weight-loss drug race.
“There’s certainly awareness of Ozempic, and increasingly with Wegovy — and we can build on that,” said Dave Moore, Novo’s US operations chief in an interview at Bloomberg’s New York headquarters. Making the pill available online, where so many consumers are purchasing weight-loss shots already, “allows us to to have the awareness at a different level,” he said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.